US 11,701,384 B2
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
Yvonne Yu-Hsuan Chen, Los Angeles, CA (US); and Meng-Yin Lin, Los Angeles, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 16/329,367
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
PCT Filed Sep. 1, 2017, PCT No. PCT/IB2017/055281
§ 371(c)(1), (2) Date Feb. 28, 2019,
PCT Pub. No. WO2018/042385, PCT Pub. Date Mar. 8, 2018.
Claims priority of provisional application 62/443,509, filed on Jan. 6, 2017.
Claims priority of provisional application 62/440,991, filed on Dec. 30, 2016.
Claims priority of provisional application 62/383,237, filed on Sep. 2, 2016.
Prior Publication US 2020/0179448 A1, Jun. 11, 2020
Int. Cl. A61K 35/17 (2015.01); C07K 14/715 (2006.01)
CPC A61K 35/17 (2013.01) [C07K 14/7155 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/03 (2013.01)] 19 Claims
 
1. A method for reducing the risk of cytokine release syndrome in a patient receiving an immunotherapy, the method comprising administering to the patient T cells comprising a heterologous nucleic acid molecule encoding an anti-IL-6Rα single chain antibody variable fragment (scFv) comprising a heavy chain variable region comprising CDR1 (SEQ ID NO:5), CDR2 (SEQ ID NO:6), and CDR3 (SEQ ID NO:7) attached by a heterologous linker to a light chain variable region comprising CDR4 (SEQ ID NO:8), CDR5 (SEQ ID NO:9), and CDR6 (SEQ ID NO:10), wherein the heterologous nucleic acid is expressed in the T cells.